Literature DB >> 27446453

MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32).

Nicoletta Coccaro1, Giuseppina Tota1, Luisa Anelli1, Antonella Zagaria1, Paola Casieri1, Angelo Cellamare1, Crescenzio Francesco Minervini1, Angela Minervini1, Cosimo Cumbo1, Luciana Impera1, Claudia Brunetti1, Paola Orsini1, Elisa Parciante1, Anna Mestice1, Giorgina Specchia1, Francesco Albano1.   

Abstract

Primary plasma cell leukemia (pPCL) is an uncommon form of plasma cell dyscrasia, and the most aggressive of the human monoclonal gammopathies. The t(11;14)(q13;q32) rearrangement is the most common alteration in pPCL, promoting cyclin D1 (CCND1) gene overexpression caused by its juxtaposition with the immunoglobulin heavy locus chromosome region. The myeloma overexpressed (MYEOV) gene maps very close to the CCND1 gene on chromosome 11, but its overexpression is rarely observed in multiple myeloma. The present study describes a case of pPCL with t(11;14) characterized by a breakpoint on der(11), unlike the one usually observed. Droplet digital polymerase chain reaction analysis revealed overexpression of CCND1 and MYEOV. To the best of our knowledge, MYEOV gene overexpression has never been previously described in pPCL.

Entities:  

Keywords:  B-Raf V600E mutation; CCND1 gene; MYEOV gene; ddPCR; primary plasma cell leukemia; t(11;14)

Year:  2016        PMID： 27446453      PMCID： PMC4950221          DOI： 10.3892/ol.2016.4759

Source DB:  PubMed          Journal:  Oncol Lett        ISSN： 1792-1074            Impact factor:   2.967


  19 in total

1.  High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones.

Authors:  P Lichter; C J Tang; K Call; G Hermanson; G A Evans; D Housman; D C Ward
Journal:  Science       Date:  1990-01-05       Impact factor: 47.728

2.  In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Authors:  Erming Tian; Jeffrey R Sawyer; Christoph J Heuck; Qing Zhang; Frits van Rhee; Bart Barlogie; Joshua Epstein
Journal:  Genes Chromosomes Cancer       Date:  2014-03-17       Impact factor: 5.006

3.  MYEOV is a prognostic factor in multiple myeloma.

Authors:  Jerome Moreaux; Dirk Hose; Amélie Bonnefond; Thierry Reme; Nicolas Robert; Hartmut Goldschmidt; Bernard Klein
Journal:  Exp Hematol       Date:  2010-09-18       Impact factor: 3.084

4.  Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).

Authors:  J W Janssen; J W Vaandrager; T Heuser; A Jauch; P M Kluin; E Geelen; P L Bergsagel; W M Kuehl; H G Drexler; T Otsuki; C R Bartram; E Schuuring
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

Review 5.  Plasma cell leukemia: from biology to treatment.

Authors:  Tomas Jelinek; Fedor Kryukov; Lucie Rihova; Roman Hajek
Journal:  Eur J Haematol       Date:  2015-03-16       Impact factor: 2.997

6.  Targeting the BRAF V600E mutation in multiple myeloma.

Authors:  Mindaugas Andrulis; Nicola Lehners; David Capper; Roland Penzel; Christoph Heining; Jennifer Huellein; Thorsten Zenz; Andreas von Deimling; Peter Schirmacher; Anthony D Ho; Hartmut Goldschmidt; Kai Neben; Marc S Raab
Journal:  Cancer Discov       Date:  2013-04-23       Impact factor: 39.397

7.  Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles.

Authors:  Laura Mosca; Pellegrino Musto; Katia Todoerti; Marzia Barbieri; Luca Agnelli; Sonia Fabris; Giacomo Tuana; Marta Lionetti; Eleonora Bonaparte; Silvia Maria Sirchia; Vitina Grieco; Gabriella Bianchino; Fiorella D'Auria; Teodora Statuto; Carmela Mazzoccoli; Luciana De Luca; Maria Teresa Petrucci; Fortunato Morabito; Massimo Offidani; Francesco Di Raimondo; Antonietta Falcone; Tommaso Caravita; Paola Omedè; Mario Boccadoro; Antonio Palumbo; Antonino Neri
Journal:  Am J Hematol       Date:  2012-10-09       Impact factor: 10.047

8.  Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels.

Authors:  Katja Specht; Eugenia Haralambieva; Karin Bink; Marcus Kremer; Sonja Mandl-Weber; Ina Koch; Raju Tomer; Heinz Hofler; Ed Schuuring; Philip M Kluin; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Blood       Date:  2004-04-13       Impact factor: 22.113

Review 9.  IMWG consensus on risk stratification in multiple myeloma.

Authors:  W J Chng; A Dispenzieri; C-S Chim; R Fonseca; H Goldschmidt; S Lentzsch; N Munshi; A Palumbo; J S Miguel; P Sonneveld; M Cavo; S Usmani; B G M Durie; H Avet-Loiseau
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

10.  Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice.

Authors:  H Lovec; A Grzeschiczek; M B Kowalski; T Möröy
Journal:  EMBO J       Date:  1994-08-01       Impact factor: 11.598
View more
  3 in total

1.  Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemia.

Authors:  Angela Minervini; Crescenzio Francesco Minervini; Luisa Anelli; Antonella Zagaria; Paola Casieri; Nicoletta Coccaro; Cosimo Cumbo; Giuseppina Tota; Luciana Impera; Paola Orsini; Claudia Brunetti; Annamaria Giordano; Giorgina Specchia; Francesco Albano
Journal:  Oncotarget       Date:  2016-12-27

Review 2.  Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies.

Authors:  Nicoletta Coccaro; Giuseppina Tota; Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Francesco Albano
Journal:  Int J Mol Sci       Date:  2020-04-29       Impact factor: 5.923

3.  Circulating Tumor DNA: Less Invasive, More Representative Method to Unveil the Genomic Landscape of Newly Diagnosed Multiple Myeloma Than Bone Marrow Aspirates.

Authors:  Yang Liu; Jiapei Guo; Yuting Yi; Xuan Gao; Lei Wen; Wenbing Duan; Zhaohong Wen; Yaoyao Liu; Yanfang Guan; Xuefeng Xia; Ling Ma; Rong Fu; Lihong Liu; Xiaojun Huang; Qing Ge; Jin Lu
Journal:  Cancers (Basel)       Date:  2022-10-07       Impact factor: 6.575
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.